Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.630
-0.010 (-0.61%)
At close: Mar 6, 2026, 4:00 PM EST
1.670
+0.040 (2.45%)
After-hours: Mar 6, 2026, 7:58 PM EST
Palisade Bio Employees
Palisade Bio had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,403,250
Market Cap
242.88M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
Employee RankingsPALI News
- 5 days ago - Palisade Bio Announces Participation in Two Upcoming Investor Conferences - GlobeNewsWire
- 12 days ago - Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 - GlobeNewsWire
- 18 days ago - Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board - GlobeNewsWire
- 26 days ago - Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - GlobeNewsWire
- 4 weeks ago - Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 5 weeks ago - Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board - GlobeNewsWire
- 7 weeks ago - Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - GlobeNewsWire
- 2 months ago - Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 - GlobeNewsWire